Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 2/20 | 0.34 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | F7 | P08709 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | F3 | P13726 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15049805 | 0.87 | HTR2A (0.39) | HTR2CHTR2AHTR2BPNMTHTT | |
| SCHEMBL2280630 | 0.82 | HTR2A (0.42) | HTR2CHTR2AHTR2BPNMTHTT | |
| SCHEMBL7472008 | 0.77 | DRD2 (0.41) | — | |
| SCHEMBL1599265 | 0.73 | PNMT (0.39) | PNMTHTTSRD5A1SRD5A2AHR | |
| SCHEMBL6847406 | 0.73 | CASP1 (0.41) | TYMS | |
| SCHEMBL2242735 | 0.73 | NOTUM (0.33) | HTR2CHTR2AHTR2BSRD5A1TYMS | |
| SCHEMBL30715534 | 0.71 | HTR2A (0.41) | HTR2CHTR2AHTR2BPNMTHTT | |
| SCHEMBL20721930 | 0.68 | AHR (0.40) | HTR2CHTR2AHTR2BPNMTHTT | |
| SCHEMBL17288395 | 0.68 | NOTUM (0.38) | HTR2CHTR2AHTR2BPNMTSRD5A1 | |
| SCHEMBL17288494 | 0.68 | PNMT (0.46) | PNMTKDM1ACYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023148206-A1 | MICROBIOCIDAL N-AMIDE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2023-08-10 | — | — | WO | claimed |
| US-10154995-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-12-18 | — | — | US | claimed |
| EP-3089788-B1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH INC (US) | 2018-10-24 | — | — | EP | claimed |
| US-20170348310-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-12-07 | — | — | US | claimed |
| US-9763942-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2017-09-19 | — | — | US | claimed |
| US-20160303126-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-20 | — | — | US | claimed |
| US-7122547-B1 | Anthranilic acid amides and the use thereof as medicaments | SCHERING AG (DE) | 2006-10-17 | — | — | US | claimed |
| WO-2004058702-A2 | 4-[(4-(CARBOXYETHYL) PIPERIDINYL) METHYL] PYRROLIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | claimed |
| EP-1129074-A2 | ANTRHRANILIC ACID AMIDES AND THE USE THEREOF AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-09-05 | — | — | EP | claimed |
| WO-2000027819-A2 | ANTRHRANILIC ACID AMIDES AND THE USE THEREOF AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-05-18 | — | — | WO | claimed |
| WO-2023148206-A1 | MICROBIOCIDAL N-AMIDE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2023-08-10 | — | — | WO | disclosed |
| US-10154995-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-12-18 | — | — | US | disclosed |
| EP-3089788-B1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH INC (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-2952096-B1 | Amide compound, an arthropod pest control agent and a method for controlling arthropod pest | SUMITOMO CHEMICAL CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-20170348310-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2017-12-07 | — | — | US | disclosed |
| WO-2007014290-A2 | FUNGICIDAL CARBOXAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-02-01 | — | — | WO | disclosed |
| US-7122547-B1 | Anthranilic acid amides and the use thereof as medicaments | SCHERING AG (DE) | 2006-10-17 | — | — | US | disclosed |
| WO-2006013210-A2 | 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2006-02-09 | — | — | WO | disclosed |
| EP-1129074-A2 | ANTRHRANILIC ACID AMIDES AND THE USE THEREOF AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027819-A2 | ANTRHRANILIC ACID AMIDES AND THE USE THEREOF AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303126-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, TTBK1, MAP3K11 | HTR2C 4040/4885HTR2A 4135/4885HTR2B 4247/4885 |
| US-10154995-B2 | Serine/threonine kinase inhibitors | MAP3K1, TTBK1, MAP3K11 | HTR2C 4040/4885HTR2A 4135/4885HTR2B 4247/4885 |
| US-20170348310-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, TTBK1, MAP3K11 | HTR2C 4040/4885HTR2A 4135/4885HTR2B 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.